Original scientific paper
THE IMPACT OF HYPOGLYCEMIA AND EPA AND DHA SUPPLEMENTATION ON BRAIN-DERIVED NEUROTROPHIC FACTOR LEVEL IN PREGNANT WOMEN WITH TYPE 1 DIABETES: A PROSPECTIVE COHORT STUDY
Marina Ivanišević
orcid.org/0000-0001-6478-1174
; Referral Center for Diabetes in Pregnancy, Ministry of Health Republic of Croatia, Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
Marina Horvatiček
; Institute Rudjer Boskovic, Zagreb, Croatia
Maja Vučić-Lovrenčić
; University Clinic Vuk Vrhovac, Zagreb, Croatia
Sandra Vučković- Rebrina
; University Clinic Vuk Vrhovac, Zagreb, Croatia
Darko Marčinko
; Department of Psychiatry and Psychological Medicine, University Hospital Center Zagreb, Zagreb, Croatia
Mirta Starčević
; Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
Josip Đelmiš
; Referral Center for Diabetes in Pregnancy, Ministry of Health Republic of Croatia, Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
Abstract
Background: In addition to its neuroprotective effect, Brain-derived neurotrophic factor (BDNF) also plays a role in glucose
and lipid metabolism. This study aims: a) to find changes in the BDNF concentration during pregnancy in type 1 diabetes. b) to
prove the effect of DHA and EPA supplementation on changes in BDNF concentrations c) to investigate the impact of hypoglycemia
on BDNF concentration.
Subjects and methods: The data from this study were from the PRE-HYPO cohort study. Twenty-one of them were on a standard
diabetic diet enriched with EPA and DHA (EPA 120 mg/day and DHA 616 mg/day; Exposed group), and nineteen pregnant diabetic
women were on the standard diabetic diet without EPA and DHA supplementation (Non-exposed group). In the first trimester of
pregnancy, fift .9 mmol/L; HYPO+ group), and twenty-five pregnant
women did not have hypoglycemia episodes (HYPO- group).
Results: BDNF concentration significantly decreased during pregnancy from the first to the third trimester, in Non-exposed from
25.1 (22.0-30.2) to 22.1 (16.3-28.2), P<0.05, in the Exposed group from 22.1 (19.8-25.9) to 18.1 (14.8-18.9), P<0.01. Pregnant
patients with hypoglycemia episodes (HYPO+ subgroup) had significantly higher BDNF in the third trimester of pregnancy [22.5
(20.6-28.4)] when compared with patients who did not develop hypoglycemia [16.3 (14.3-18.8), P<0.001]. In the third trimester of
pregnancy, BDNF and n-6 PUFAs were associated with hypoglycemia (OR 1.818 95 % CI 1.079-3.003, P=0.025; OR 1.103 95 % CI
1.001-1.217, P=0.048). Total F.A.s were inversely associated with hypoglycemia (OR 0.969 95% CI 0.939-0.998, P=0.048).
Conclusion: Pregnant women with hypoglycemia (HYPO+ group) had higher concentrations of BDNF in the first and third
trimesters of pregnancy compared to those without hypoglycemia. An increase in body weight during pregnancy leads to a decrease
in BDNF concentration.
Keywords
Brain; derived neurotrophic factor; diabetes mellitus type 1; EPA; DHA; hypoglycemia; pregnancy
Hrčak ID:
266976
URI
Publication date:
4.10.2021.
Visits: 728 *